<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOLTERODINE TARTRATE</span><br/>(tol-ter'o-deen tar'trate)<br/><span class="topboxtradename">Detrol, </span><span class="topboxtradename">Detrol LA<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic agent</span>; <span class="classification">antimuscarinic agent</span>; <span class="classification">muscarinic receptor antagonist</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg tablets; 2 mg, 4 mg sustained release</p>
<h1><a name="action">Actions</a></h1>
<p>Selective muscarinic urinary bladder receptor antagonist.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces urinary incontinence, urgency, and frequency. Controls urinary bladder incontinence by controlling contractions.</p>
<h1><a name="uses">Uses</a></h1>
<p>Overactive bladder (urinary frequency, urgency, urge incontinence).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Gastric retention; hypersensitivity to tolterodine; uncontrolled narrow-angle glaucoma; urinary retention; pregnancy (category
         C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; cardiovascular disease; liver disease; controlled narrow-angle glaucoma; obstructive GI disease; obstructive uropathy;
         paralytic ileus or intestinal atony; renal impairment; ulcerative colitis.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Overactive Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 mg b.i.d. or 4 mg sustained release q.d.<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>May decrease to 1 mg b.i.d. or 2 mg sustained release q.d. in those with significantly reduced liver function or taking drugs
               that inhibit cytochrome P450 3A4 (see <small>ADMINISTRATION</small>)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not crush or chew sustained release tablets. These must be swallowed whole.</li>
<li>Do not give doses &gt;1 mg b.i.d. to those with significantly reduced liver function or concurrently receiving macrolide antibiotics,
            azole antifungal agents, or other cytochrome P450 3A4 inhibitors.
         </li>
<li>Store at 20°25° C (68°77° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Back pain, fatigue, flu-like syndrome, falls, arthralgia, weight gain. <span class="typehead">CNS:</span> Headache, paresthesias, vertigo, dizziness, nervousness, somnolence. <span class="typehead">CV:</span> Chest pain, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Dry mouth,</span> dyspepsia, constipation, abdominal pain, diarrhea, flatulence, nausea, vomiting. <span class="typehead">Urogenital:</span> Dysuria, micturition frequency, urinary retention, UTI. <span class="typehead">Respiratory:</span> Bronchitis, cough, pharyngitis, rhinitis, sinusitis, URI. <span class="typehead">Skin:</span> Pruritus, rash, erythema, dry skin. <span class="typehead">Special Senses:</span> Dry eyes, vision abnormalities. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive anticholinergic effects with <b>amantadine,</b> <b>amoxapine,</b> <b>bupropion,</b> <b>clozapine,</b> <b>cyclobenzaprine,</b> <b>disopyramide,</b> <b>maprotiline,</b> <b>olanzapine,</b> <b>orphenadrine,</b> <span class="classification">sedating h<sub>1</sub>-blockers</span>, <span class="classification">phenothiazines</span>, <span class="classification">tricyclic antidepressants</span>. <span class="typehead">Food:</span> <b>Grapefruit juice</b> may increase <b>tolterodine</b> levels in some patients. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 77% absorbed, significantly decreased with food. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> 96% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 2D6 enzymes to active metabolite. <span class="typehead">Elimination:</span> 77% excreted in urine, 17% in feces. <span class="typehead">Half-Life:</span> 1.93.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor intraocular pressure more frequently with glaucoma patients.</li>
<li>Monitor vital signs carefully (HR and BP), especially in those with cardiovascular disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician promptly if you experience eye pain, rapid heartbeat, difficulty breathing, skin rash or hives, confusion,
            or incoordination.
         </li>
<li>Report blurred vision, sensitivity to light, and dry mouth (all common adverse effects) to physician if bothersome.</li>
<li>Avoid the use of alcohol or OTC antihistamines.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>